Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ANNX
- Price
- 5.04
- Stock movement up
- +0.22 (4.04%)
- Company name
- Annexon Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 843.66M
- Ent value
- 771.94M
- Price/Sales
- 247.84
- Price/Book
- 5.23
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -20.89%
- 1 year return (CAGR)
- 112.78%
- 3 year return (CAGR)
- 4.22%
- 5 year return (CAGR)
- -27.74%
- 10 year return (CAGR)
- -
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ANNX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 247.84 |
| Price to Book | 5.23 |
| EV to Sales | 226.77 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 149.06M |
| EPS (TTM) | -1.39 |
| FCF per share (TTM) | -1.18 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.40M |
| Gross profit (TTM) | -106.00K |
| Operating income (TTM) | -218.63M |
| Net income (TTM) | -207.02M |
| EPS (TTM) | -1.39 |
| EPS (1y forward) | -1.19 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -3.11% |
| Operating margin (TTM) | -6422.68% |
| Profit margin (TTM) | -6081.79% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 139.42M |
| Net receivables | 0.00 |
| Total current assets | 192.82M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 35.54M |
| Total assets | 229.14M |
| Accounts payable | 18.22M |
| Short/Current long term debt | 26.94M |
| Total current liabilities | 43.58M |
| Total liabilities | 67.70M |
| Shareholder's equity | 161.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -176.44M |
| Capital expenditures (TTM) | 143.00K |
| Free cash flow (TTM) | -176.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -128.23% |
| Return on Assets | -90.35% |
| Return on Invested Capital | -126.03% |
| Cash Return on Invested Capital | -107.51% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.62 |
| Daily high | 5.88 |
| Daily low | 5.58 |
| Daily Volume | 1.60M |
| All-time high | 35.01 |
| 1y analyst estimate | 14.33 |
| Beta | 1.18 |
| EPS (TTM) | -1.39 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 9 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ANNX | S&P500 | |
| Current price drop from All-time high | -85.60% | -1.82% |
| Highest price drop | -96.06% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -72.55% | -10.84% |
| Avg time to new high | 88 days | 12 days |
| Max time to new high | 1255 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
843.66M
Marketcap category
Small-cap
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Employees
99
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page